Recruiting

Tigertriever

Sponsor:

Henry Ford Health System

Code:

NCT07363525

Conditions

Blood Clot

Thrombectomy

Ischemic Stroke

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Mechanical Thrombectomy

Study Details

Brief summary:

The purpose of this research study is to collect data about the effectiveness (i.e. how the device works) and safety (how safe it is to use such a device) of the Tigertriever in restoring blood flow by removing thrombus (or blood clot) from a large intracranial vessel (blood vessel in the brain) in patients experiencing ischemic stroke within 8 hours of symptom onset.

Conditions

Blood Clot

Thrombectomy

Ischemic Stroke

Study ID

NCT07363525

Start date

Jan 15, 2026

Status verified date

May, 2026

Completion date

Dec 31, 2028

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as per the approved indication.
2. Tigertriever was used as the first line treatment in the target vessel.
3. A signed informed consent.
4. Age ≥ 18.

Exclusion Criteria:

-1. Evidence of acute brain hemorrhage on NCCT or MR at admission. 2. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months.

3\. pre-stroke disability (pre-stroke mRS ≥ 2).

Study Design

Enrollment

150 participants

Anticipated

Interventions and Outcome Measures

Arms

Thrombectomy Treated Patients

Patients are enrolled only if the use of the Tigertreiver is used during surgery.

Interventions

Mechanical Thrombectomy

You will be asked to provide medical history, take neurological exams in the form of questionnaires, and provide imaging data.

Primary outcome measure

  • Modified Rankin Scale [ Time Frame: From enrollment to 90 days post treatment ]
  • Primary Effectiveness Endpoint [ Time Frame: By the end of the thrombectomy procdure. ]
  • Primary Effectiveness Endpoint - mTICI [ Time Frame: From time of event to after the first thrombectomy pass. ]

Central Contacts and Locations

Central contacts

Alex Chebl, MD

313-916-2644achebl1@hfhs.org

Kelly Tundo, RN

313-916-1102kciach1@hfhs.org

Locations

Henry Ford Hospital

Recruiting

Detroit, Michigan, United States, 48202

Contacts

Alex B Chebl, MD

3132070432achebl1@hfhs.org

Kelly Tundo

KCIACH1@hfhs.org

More Information

Sponsor

Henry Ford Health System

Last update posted

May 8, 2026

Last verified

May, 2026

Keywords

  • thrombus
  • Clot
  • Device
  • Stroke

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Henry Ford Health System on 2026-05-08.